News capsules. Cardiovascular risk burden for women on the rise, while men see improvement.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2010 AND VI 45 AND IP 2
Results: 27
1
2
News capsules. Low-dose drug combination shows better outcomes for myeloma patients.
- Published in:
- 2010
- Publication type:
- Journal Article
3
Editor's letter.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
4
News capsules. Disease-modifying antirheumatic drugs prove most cost-effective in very early RA.
- Published in:
- 2010
- Publication type:
- Journal Article
5
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
6
Exenatide LAR: a sustained-release formulation of exenatide for the treatment of type 2 diabetes.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
7
Meeting coverage. Higher dosage of losartan needed for maximal benefit in patients with CHF and left ventricular dysfunction.
- Published in:
- 2010
- Publication type:
- Journal Article
8
Meeting coverage. ER niacin bests ezetimibe on measure of atherosclerosis.
- Published in:
- 2010
- Publication type:
- Journal Article
9
Medication safety and reliability. FDA finds no increased cardiovascular risk in patients using tiotropium.
- Published in:
- 2010
- Publication type:
- Journal Article
10
Renal diseases.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 72
- Publication type:
- Article
11
ER niacin bests ezetimibe on measure of atherosclerosis.
- Published in:
- 2010
- Publication type:
- Conference Paper/Materials
12
Higher dosage of losartan needed for maximal benefit in patients with CHF and left ventricular dysfunction.
- Published in:
- 2010
- Publication type:
- Proceeding
13
FDA Commissioner Hamburg builds agency's capabilities for bringing new therapies to patients.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 69
- Publication type:
- Article
14
FDA finds no increased cardiovascular risk in patients using tiotropium.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 68
- Publication type:
- Article
15
Low-dose drug combination shows better outcomes for myeloma patients.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 67
- Publication type:
- Article
16
Disease-modifying antirheumatic drugs prove most cost-effective in very early RA.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 66
- Publication type:
- Article
17
Cardiovascular risk burden for women on the rise, while men see improvement.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 62
- Publication type:
- Article
18
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 52
- Publication type:
- Article
19
Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 43
- Publication type:
- Article
20
FDA actions in brief.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 42
- Publication type:
- Article
21
First-time generic approvals.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 42
- Publication type:
- Article
22
An antiepileptic drug approved for the treatment of refractory complex partial seizures in adults and spasms in Infants.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 41
- Publication type:
- Article
23
A plasma kallikreln inhibitor approved for the treatment of acute attacks of hereditary angioedema.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 41
- Publication type:
- Article
24
Pipeline preview.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 41
- Publication type:
- Article
25
Editor's Letter.
- Published in:
- Formulary, 2010, v. 45, n. 2, p. 39
- Publication type:
- Article
26
Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes.
- Published in:
- 2010
- Publication type:
- Abstract
27
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis.
- Published in:
- 2010
- Publication type:
- Abstract